ANGIOMAX (bivalirudin)
THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION·+2
MEDICINES COMP.
Indication
Thrombosis with heparin-induced thrombocytopenia during percutaneous coronary intervention
Thrombosis with heparin-induced thrombocytopenia during percutaneous coronary intervention refers to acute thromboembolic complications arising in cardiovascular patients who develop or have immune-mediated heparin-induced thrombocytopenia (HIT) while undergoing catheter-based revascularization. Read more about Thrombosis with heparin-induced thrombocytopenia during percutaneous coronary intervention
21 drugs 21 manufacturers
Drugs that treat it
Common Thrombosis with heparin-induced thrombocytopenia during percutaneous coronary intervention therapies.
BIVALIRUDIN
THROMBIN INHIBITORS (NON-HEPARINOID)·THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION·+2
SANDOZ
BIVALIRUDIN
THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION·+2
HOSPIRA
BIVALIRUDIN
THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION·+2
Sandoz
BIVALIRUDIN
THROMBIN INHIBITORS (NON-HEPARINOID)·THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION·+2
FRESENIUS KABI
ANGIOMAX (bivalirudin)
THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION·+2
THE MEDICINES C
BIVALIRUDIN
THROMBIN INHIBITORS (NON-HEPARINOID)·THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION·+2
DR.REDDY'S LAB
BIVALIRUDIN
THROMBIN INHIBITORS (NON-HEPARINOID)·THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION·+2
APOTEX CORP
BIVALIRUDIN
THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION·+2
Hospira
Filter & compare in the drug finder →Opens the drug finder with Thrombosis with heparin-induced thrombocytopenia during percutaneous coronary intervention preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonThrombosis with heparin-induced thrombocytopenia during percutaneous coronary intervention refers to acute thromboembolic complications arising in cardiovascular patients who develop or have immune-mediated heparin-induced thrombocytopenia (HIT) while undergoing catheter-based revascularization.
Pathophysiologically, IgG antibodies form against platelet factor 4–heparin complexes, binding to platelet Fc?RIIa receptors and provoking platelet activation, consumptive thrombocytopenia, and excessive thrombin generation.
This intense prothrombotic state interacts with procedure-related endothelial disruption and intracoronary instrumentation, significantly increasing the risk of acute coronary occlusion, stent thrombosis, or systemic thromboembolism.
Because standard heparin-based anticoagulation is strictly contraindicated, this specific procedural setting requires prompt non-heparin anticoagulation to avert ischemic vessel compromise and procedural failure.
- perfusion.com
Thrombosis with heparin-induced thrombocytopenia during percutaneous coronary intervention refers to acute thromboembolic complications arising in cardiovascular patients who develop or have immune-mediated heparin-induced thrombocytopenia (HIT) while undergoing catheter-based revascularization This intense prothrombotic state interacts with procedure-related endothelial disruption and intracoronary instrumentation, significantly increasing the risk of acute coronary occlusion, stent thrombosis,...
- nih.gov
Thrombosis with heparin-induced thrombocytopenia during percutaneous coronary intervention refers to acute thromboembolic complications arising in cardiovascular patients who develop or have immune-mediated heparin-induced thrombocytopenia (HIT) while undergoing catheter-based revascularization Pathophysiologically, IgG antibodies form against platelet factor 4–heparin complexes, binding to platelet FcγRIIa receptors and provoking platelet activation, consumptive thrombocytopenia, and excessive ...
- nih.gov
Pathophysiologically, IgG antibodies form against platelet factor 4–heparin complexes, binding to platelet FcγRIIa receptors and provoking platelet activation, consumptive thrombocytopenia, and excessive thrombin generation
- drugbank.com
Pathophysiologically, IgG antibodies form against platelet factor 4–heparin complexes, binding to platelet FcγRIIa receptors and provoking platelet activation, consumptive thrombocytopenia, and excessive thrombin generation
- hmpgloballearningnetwork.com
This intense prothrombotic state interacts with procedure-related endothelial disruption and intracoronary instrumentation, significantly increasing the risk of acute coronary occlusion, stent thrombosis, or systemic thromboembolism
- fda.gov
Because standard heparin-based anticoagulation is strictly contraindicated, this specific procedural setting requires prompt non-heparin anticoagulation to avert ischemic vessel compromise and procedural failure
- fda.gov
Because standard heparin-based anticoagulation is strictly contraindicated, this specific procedural setting requires prompt non-heparin anticoagulation to avert ischemic vessel compromise and procedural failure
Personalize your experience
Follow Thrombosis with heparin-induced thrombocytopenia during percutaneous coronary intervention and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.